ScoreWhy is Jenburkt Pharmaceuticals Ltd. ?
1
High Management Efficiency with a high ROE of 18.99%
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 8.47% and Operating profit at 14.38% over the last 5 years
- PBDIT(Q) Highest at Rs 14.25 cr.
- OPERATING PROFIT TO NET SALES(Q) Highest at 31.93%
- PBT LESS OI(Q) Highest at Rs 13.31 cr.
4
With ROE of 20.7, it has a Expensive valuation with a 2.8 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 16.28%, its profits have risen by 18.1% ; the PEG ratio of the company is 0.7
5
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
6
Market Beating performance in long term as well as near term
- Along with generating 16.28% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Jenburkt Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Jenburkt Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Jenburkt Pharma
16.28%
0.42
38.46%
Sensex
-3.33%
-0.25
13.43%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.47%
EBIT Growth (5y)
14.38%
EBIT to Interest (avg)
32.51
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
1.00
Tax Ratio
25.34%
Dividend Payout Ratio
25.99%
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
35.97%
ROE (avg)
18.99%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
13
Industry P/E
34
Price to Book Value
2.78
EV to EBIT
12.33
EV to EBITDA
11.45
EV to Capital Employed
2.86
EV to Sales
2.97
PEG Ratio
0.74
Dividend Yield
NA
ROCE (Latest)
22.13%
ROE (Latest)
20.70%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
PBDIT(Q)
Highest at Rs 14.25 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 31.93%
PBT LESS OI(Q)
Highest at Rs 13.31 cr.
PAT(Q)
Highest at Rs 13.98 cr.
EPS(Q)
Highest at Rs 24.60
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Jenburkt Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 13.31 cr has Grown at 44.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 9.20 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 13.98 cr has Grown at 72.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 8.11 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 14.25 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 31.93%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 13.31 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 13.98 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 24.60
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Jenburkt Pharma
Non Operating Income - Quarterly
Highest at Rs 4.35 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
